Острые формы ишемической болезни сердца при обострении хронической обструктивной болезни легких: эпидемиология, диагностика и лечение

Хроническая обструктивная болезнь легких (ХОБЛ) является одной из основных проблем здравоохранения в мире. ХОБЛ тесно связана с коморбидными сердечно-сосудистыми заболеваниями (ССЗ), утяжеляющими ХОБЛ и повышающими риск смерти. Частота и распространенность ССЗ пи ХОБЛ составляет около 64 %. Примерно у 30 % пациентов с ХОБЛ наступает летальный исход от сердечно-сосудистых осложнений (ССО). Последние данные свидетельствуют о повышенном риске острого ИМ при тяжелом обострении ХОБЛ. Риск развития ССО увеличивается при тахикардии, повышении окислительного стресса и системном воспалении. По данным ряда исследований, для ранней диагностики ССО могут быть полезны не только методы визуализации, но и электрокардиография, а также анализ крови на биомаркеры. Несмотря на доказанные преимущества, некоторые препараты, обладающие способностью изменить прогноз при сердечно-сосудистой патологии, в частности кардиоселективные β-адреноблокаторы, у больных ХОБЛ используются недостаточно. Данный обзор посвящен некоторым аспектам обострения ХОБЛ и риска ССЗ.

1. Corrao S., Brunori G., Lupo U., Perticone F. Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities. Eur. Respir. Rev. 2017; 26 (145): pii: 160123. DOI: 10.1183/16000617.0123-2016.

2. Mullerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013; 144 (4): 1163–1178. DOI: 10.1378/chest.12-2847.

3. Rothnie K.J., Connell O., Müllerová H. et al. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. 2018; 15 (8): 935–946. DOI: 10.1513/AnnalsATS.201710-815OC.

4. Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27 (1): 13-20. DOI: 10.18093/0869-0189-2017-27-1-13-20.

5. Chen W., Thomas J., Sadatsafavi M., Fitz Gerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir. Med. 2015; 3 (8): 631–639. DOI: 10.1016/S2213-2600(15)00241-6.

6. Berger J.S., Sanborn T.A., Sherman W., Brown D.L. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am. J. Cardiol. 2004; 94 (5): 649–651.

7. Campo G., Guastaroba P., Marzocchi A. et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013; 144 (3): 750–757. DOI: 10.1378/chest.12-2313.

8. Feary J.R., Rodrigues L.C., Smith C.J. et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010; 65 (11): 956–962. DOI: 10.1136/thx.2009.128082.

9. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: Phenomenon or epiphenomenon? Proc. Am. Thorac. Soc. 2004; 1 (2): 109–114. Available at: https://www.atsjournals.org/doi/pdf/10.1513/pats.2306029

10. Wedzicha J.A. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2004; 1 (2): 115–120. DOI: 10.1513/pats.2306030.

11. Wedzicha J.A., Seemungal T.A., MacCallum P.K. et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb. Haemost. 2000; 84 (2): 210–215.

12. Chen Y.W., Leung J.M., Sin D.D. A Systematic review of diagnostic biomarkers of COPD exacerbation. PLoS ONE. 2016; 11 (7): e0158843. DOI: 10.1371/journal.pone.0158843.

13. Smeeth L., Thomas S.L., Hall A.J. et al. Risk of Myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 2004; 351 (25): 2611–2618. DOI: 10.1056/NEJMoa041747.

14. Donaldson G.C., Hurst J.R., Smith C.J. et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010; 137 (5): 1091–1097. DOI: 10.1378/chest.09-2029.

15. Brekke P.H., Omland T., Smith P., Soyseth V. Underdiagnosis of myocardial infarction in COPD-Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir. Med. 2008; 102 (9): 1243–1247. DOI: 10.1016/j.rmed.2008.04.010.

16. McAllister D.A., Maclay J.D., Mills N.L. et al. Diagnosis of myocardial infarction following hospitalization for exacerbation of COPD. Eur. Respir. J. 2012; 39 (5): 1097–1103. DOI: 10.1183/09031936.00124811.

17. Kunisaki K.M., Dransfield M.T., Anderson J.A. et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events: A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am. J. Respir. Crit. Care Med. 2018; 198 (1): 51–57. DOI: 10.1164/rccm.201711-2239OC.

18. Rabe K.F., Hurst J.R., Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur. Respir. Rev. 2018; 27 (149): pii: 180057. DOI: 10.1183/16000617.0057-2018.

19. Meier C.R., Jick S.S., Derby L.E. et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet. 1998; 351 (9114): 1467–1471. DOI: 10.1016/s0140-6736(97)11084-4.

20. Clayton T.C., Thompson M., Meade T.W. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur. Heart J. 2008; 29 (1): 96–103. DOI: 10.1093/eurheartj/ehm516.

21. Hill J., Heslop C., Man S.F. et al. Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. Eur. Heart J. 2011; 32 (15): 1918–1925. DOI: 10.1093/eurheartj/ehr124.

22. Van Eeden S.F., Sin D.D. Chronic obstructive pulmonary disease: A chronic systemic inflammatory disease. Respiration. 2008; 75 (2): 224–238. Available at: https://www.karger.com/Article/Abstract/111820

23. Danesh J., Wheeler J.G., Hirschfield G.M. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004; 350 (14): 1387–1397. DOI: 10.1056/NEJMoa032804.

24. Vanhaverbeke M., Veltman D., Pattyn N. et al. CRP-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up Running head: CRP during and after myocardial infarction. Clin. Cardiol. 2018; 41 (9): 1201–1206. DOI: 10.1002/clc.23017.

25. Maclay J.D., McAllister D.A., Johnston S. et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011; 66 (9): 769–774. DOI: 10.1136/thx.2010.157529.

26. Malerba M., Clini E., Malagola M., Avanzi G.C. Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. Expert. Rev. Hematol. 2013; 6 (4): 475–483. DOI: 10.1586/17474086.2013.814835.

27. Perski A., Olsson G., Landou C. et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am. Heart J. 1992; 123 (3): 609–616. DOI: 10.1016/0002-8703(92)90497-j.

28. Heidland U.E., Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001; 104 (13): 1477–1482. DOI: 10.1161/hc3801.096325.

29. Hoiseth A.D., Omland T., Hagve T.A. et al. Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. BMC Pulm. Med. 2012; 12: 22. DOI: 10.1186/1471-2466-12-22.

30. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular event sandall-cause mortality with arterial stiffness: A systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010; 55 (13): 1318–1327. DOI: 10.1016/j.jacc.2009.10.061.

31. Vlachopoulos C., Alexopoulos N., Stefanadis C. Fast in the aorta, slow in the coronaries. Cardiology. 2010; 116 (4): 257–260. DOI: 10.1159/000319599.

32. Patel A.R., Kowlessar B.S., Donaldson G.C. et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 188 (9): 1091–1099. DOI: 10.1164/rccm.201306-1170OC.

33. Макарова М.А., Авдеев С.Н., Чучалин А.Г. Гипоксемия как потенциальный фактор развития эндотелиальной дисфункции и артериальной ригидности у больных хронической обструктивной болезнью легких. Пульмонология. 2013; (3): 36–40. DOI: 10.18093/0869-0189-2013-0-3-36-40.

34. Stewart A.G., Waterhouse J.C., Howard P. Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. Eur. Respir. J. 1991; 4 (10): 1207–1214.

35. Rothnie K.J., Smeeth L., Herrett E. et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015; 101 (14): 1103–1110. DOI: 10.1136/heartjnl-2014-307251.

36. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 2007; 50 (22): 2173–2195. DOI: 10.1016/j.jacc.2007.09.011.

37. Nordenskjöld A.M., Hammar P., Ahlström H. et al. Unrecognized myocardial infarction assessed by cardiac magnetic resonance imaging is associated with adverse long-term prognosis. PLoS ONE. 2018; 13 (7): e0200381. DOI: 10.1371/journal.pone.0200381.

38. Budoff M.J., Dowe D., Jollis J.G. et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J. Am. Coll. Cardiol. 2008; 52 (21): 1724–1732. DOI: 10.1016/j.jacc.2008.07.031.

39. Budoff M.J., Nasir K., Kinney G.L. et al. Coronary artery and thoracic calcium on non-contrast thoracic CT scans: comparison of ungated and gated examinations in patients from the COPD Gene cohort. J. Cardiovasc. Comput. Tomogr. 2011; 5 (2): 113–118. DOI: 10.1016/j.jcct.2010.11.002.

40. Pavasini R., d’Ascenzo F., Campo G. et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analysis. Int. J. Cardiol. 2015; 191: 187–193. DOI: 10.1016/j.ijcard.2015.05.006.

41. Buchan A., Bennett R., Coad A. et al. The role of cardiac biomarkers for predicting left ventricular dysfunction and cardiovascular mortality in acute exacerbations of COPD. Open Heart. 2015; 2 (1): e000052. DOI: 10.1136/openhrt-2014-000052.

42. Marcun R., Sustic A., Brguljan P.M. et al. Cardiac biomarkers predict outcome after hospitalization for an acute exacerbation of chronic obstructive pulmonary disease. Int. J. Cardiol. 2012; 161 (3): 156–159. DOI: 10.1016/j.ijcard.2012.05.044.

43. Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J. Cardiol. 2017; 70 (2): 128–134. DOI: 10.1016/j.jjcc.2017.03.001.

44. Harrison M.T., Short P., Williamson P.A. et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014; 69 (7): 609–615. DOI: 10.1136/thoraxjnl-2013-203996.

45. Pavasini R., Biscaglia S., d’Ascenzo F. et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD. 2016; 13 (4): 509–514. DOI: 10.3109/15412555.2015.1099620.

46. Goto Y., Faridi M.K., Camargo C.A., Hasegawa K. The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study. NPJ Prim. Care Respir. Med. 2018; 28 (1): 7. DOI: 10.1038/s41533-018-0074-x.

47. Schwameis R., Pils S., Weber M. et al. Acetylic salicylic acid for the treatment of chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial. Pharmacology. 2016; 98 (1-2): 93–98. DOI: 10.1159/000446349.

48. Domanski M.J., Krause-Steinrauf H., Massie B.M. et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J. Card. Fail. 2003; 9 (5): 354–363.

49. Puente-Maestu L., Calle M., Ortega-González Á. et al. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir. Med. 2014; 108 (5): 737–744. DOI: 10.1016/j.rmed.2014.02.009.

50. Quint J.K., Herrett E., Bhaskaran K. et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. Br. Med. J. 2013; 347: f6650. DOI: 10.1136/bmj.f6650.

51. Petta V., Perlikos F., Loukides S. et al. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Fail. Rev. 2017; 22 (6): 753–763. DOI: 10.1007/s10741-017-9646-z.

52. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2005; (4): CD003566. DOI: 10.1002/14651858.CD003566.pub2.

53. Bhatt S.P., Wells J.M., Kinney G.L. et al. β-blockers are associated with a reduction in COPD exacerbations. Thorax. 2016; 71 (1): 8–14. DOI: 10.1136/thoraxjnl-2015-207251.

54. Rutten F.H., Zuithoff N.P., Hak E. et al. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch. Intern. Med. 2010; 170 (10): 880–887. DOI: 10.1001/archinternmed.2010.112.

55. Du Q., Sun Y., Ding N., Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS ONE. 2014; 9 (11): e113048. DOI: 10.1371/journal.pone.0113048.

56. Mortensen E.M., Copeland L.A., Pugh M.J. et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir. Res. 2009; 10: 45. DOI: 10.1186/1465-9921-10-45.

57. Criner G.J., Connett J.E., Aaron S.D. et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N. Engl. J. Med. 2014; 370 (23): 2201–2210. DOI: 10.1056/NEJMoa1403086.

58. Morgan A.D., Zakeri R., Quint J.K. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther. Adv. Respir. Dis. 2018; 12: 1753465817750524. DOI: 10.1177/1753465817750524.

59. Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–1501. DOI: 10.1056/NEJMoa1303342.

60. Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI: 10.1056/NEJMoa1713901.

61. Wang M.T., Liou J.T., Lin C.W. et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern. Med. 2018; 178 (2): 229–238. DOI: 10.1001/jamainternmed.2017.7720.